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Objective: To summarize and review the utility of physical interventions in the treatment of 
psychiatric disorders.
Methods: A systematic review of the literature pertaining to novel physical interventions, 
namely, transcranial magnetic stimulation, deep brain stimulation, vagus nerve stimulation, 
and neurosurgery, was conducted using MEDLINE, EMBASE, and PSYCHLIT. Bibliogra-
phies of papers were scrutinized for further relevant references along with literature known 
to the authors.
Results: Currently available physical interventions worldwide are reviewed with respect 
to efﬁ  cacy, applications, and putative indications. Physical interventions have experienced 
a resurgence of interest for both the investigation of brain function and the treatment of 
neuropsychiatric disorders. The widespread availability of neuroimaging technology has 
advanced our understanding of brain function and allowed closer examination of the effects 
of physical treatments. Clinically, transcranial magnetic stimulation seems likely to have a 
role in the management of depression, and its use in other neuropsychiatric disorders appears 
promising. Following on from its success in the management of intractable epilepsy, vagus 
nerve stimulation is undergoing evaluation in the treatment of depression with some success 
in refractory cases. Deep brain stimulation has improved mood in patients with Parkinson’s 
disease and may also relieve symptoms of obsessive-compulsive disorder. Neurosurgery has 
re-invented itself by way of increased technical sophistication, and although further assessment 
of its efﬁ  cacy and clinical utility is still needed, its widespread practice reﬂ  ects its increasing 
acceptance as a viable treatment of last resort.
Conclusion: It is clear that physical treatments are here to stay and “getting physical” offers 
a useful addition to the neuropsychiatrist’s therapeutic armamentarium. However, like all new 
treatments these interventions need to remain under rigorous scientiﬁ  c scrutiny to determine 
accurately their immediate and long-term effects.
Keywords: physical treatments, psychosurgery, transcranial magnetic stimulation, vagus nerve 
stimulation, deep brain stimulation, neuropsychiatry
Introduction
The development of psychopharmacological treatments for psychiatric disorders 
has made physical interventions less popular, evidenced by the marked decline in 
neurosurgery since its hey-day in the 1960s. Many psychiatric patients are resistant 
to medications or are unable to tolerate their side-effects, and therefore novel treat-
ments for neuropsychiatric disorders are necessary. In the last decade, several new 
physical treatments have been introduced that hold the potential to join the mainstream 
of psychiatric therapy. In this paper we review the efﬁ  cacy of transcranial magnetic 
stimulation (TMS), vagus nerve stimulation (VNS), and deep brain stimulation (DBS) 
and the current status of neurosurgery which, although not new, continues to be Neuropsychiatric Disease and Treatment 2006:2(2) 166
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novel among neuropsychiatric treatments. Light therapy was 
excluded from this review as much of the literature pertaining 
to it is linked with seasonal affective disorder and it does not 
generally come under the rubric of “physical treatments” in 
neuropsychiatry.
Method
The literature was reviewed selectively by entering the 
search terms “transcranial magnetic stimulation”, “vagus 
nerve stimulation”, “deep brain stimulation”, “psychosur-
gery”, and “neurosurgery” into MEDLINE, EMBASE, and 
PSYCHLIT. To identify more-speciﬁ  c articles the names of 
some of the surgical procedures, eg, “stereotactic subcaudate 
tractotomy”, “capsulotomy”, “limbic leucotomy”, and 
“cingulotomy”, were entered. As few randomized controlled 
trials have been possible or indeed attempted using VNS, 
DBS, and neurosurgery, the use of strict criteria such as 
inclusion of placebo or blinding status was not possible and 
studies were hence included based on their clinical salience. 
We also included industry-sponsored trials as although 
these include an interest on the part of the sponsor, they 
have withstood quality control and audit by bodies such as 
the FDA and often have attracted the largest numbers of 
participants.
Transcranial magnetic stimulation 
(TMS)
TMS is performed by placing an electromagnetic coil on the 
scalp through which large currents are pulsed to generate 
rapidly ﬂ  uctuating magnetic ﬁ  elds. These cross the scalp 
unimpeded and generate eddy currents in the underlying 
brain cortex that depolarise neurons and produce an associ-
ated effect (Roth et al 1991) (see Figure 1a). The neural 
response is contingent upon a number of variables, such as the 
site of application, the stimulation parameters, and the use of 
single or multiple stimuli (Cohen et al 1990). The application 
of repeated TMS pulses to a particular site is termed repetitive 
TMS (rTMS) and the application at frequencies above 1Hz 
is referred to as fast-frequency repetitive TMS (FF-rTMS). 
The latter has been most investigated in neuropsychiatric 
treatment studies.
TMS in neuropsychiatric disorders
The rapid and widespread implementation of TMS over the 
last 20 years has generated considerable debate about the 
effects and implications of using this noninvasive method 
of brain stimulation.
Depression
In preclinical studies with rats TMS shows an effect similar 
to that produced by antidepressants and electroconvulsive 
shock (Ben-Shachar et al 1997; Lisanby and Belmaker 2000; 
Keck et al 2001; Levkovitz and Ng 2001). There have also 
been ﬁ  ndings that support it having an antidepressant action 
in humans, including reports that it delays the onset of rapid 
eye movement (REM) sleep in healthy subjects (Cohrs et al 
1998) and normalizes the dexamethasone suppression test 
in depressed patients (Pridmore 1999).
Guided by neuroimaging studies, the prefrontal cortex 
was proposed as a suitable target for antidepressant rTMS 
(George et al 1995), and initial studies of focal rTMS 
of the left prefrontal cortex (PFC) seemed encouraging 
(Pascual-Leone et al 1996). Comparison across studies has 
been difﬁ  cult because of differences in patient populations, 
study design, duration, and rTMS parameters. A summary 
of sham-controlled treatment trials of rTMS is shown in 
Table 1.
There have been several meta-analyses of these placebo-
controlled trials of rTMS for major depression. The Cochrane 
Collaboration (Martin et al 2003) concluded that two weeks 
of high-frequency rTMS to the left dorsolateral prefrontal 
cortex led to significant improvement on the Hamilton 
Depression Rating Scale (HDRS) (Hamilton 1960), but 
not on a self-rating scale such as Beck (Beck 1961). This 
improvement was not sustained at 2-week follow-up. 
The authors concluded that the published evidence for an 
antidepressant effect of rTMS was weak. Burt et al (2002) 
conducted an independent meta-analysis of treatment studies, 
which included controlled and uncontrolled, blind, and open 
study designs. Analysis of effects in uncontrolled studies 
found a consistent but modest treatment effect (37% mean 
reduction in HDRS) and for controlled studies the magnitude 
of change was even smaller (27% mean reduction in HDRS 
for TMS group, compared with 7% reduction for sham 
treatment). In summary, meta-analyses show that statistical 
evidence for the efﬁ  cacy of rTMS is fairly robust but that 
clinical outcomes are modest. An important caveat, though, 
is that most of the trials to date have only compared rTMS to 
a sham control over a 2-week period, whereas evidence from 
trials allowing longer treatment periods, either in an open 
extension (eg, Loo et al 1999) or within the controlled phase 
(Rumi et al 2005), suggests further improvement occurs with 
increasing duration of rTMS.
A number of studies randomized depressed subjects to 
receive electroconvulsive therapy (ECT) or 4 weeks of rTMS. 
These reported a clear advantage (Grunhaus et al 2000) Neuropsychiatric Disease and Treatment 2006:2(2) 167
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or emerging trends (Pridmore et al 2000; Janicak et al 2002) 
in favour of ECT, though one study found no difference 
(Grunhaus et al 2003). Of interest, the results of Grunhaus 
et al (2000) suggested that rTMS may be equally effective 
as ECT for treating nonpsychotic depression, but had little 
efﬁ  cacy in psychotic depression.
Investigators in the ﬁ  eld concur that there still remains 
a need for large multi-center trials with longer sham-
controlled periods and greater scientiﬁ  c rigor including 
appropriate and documented randomization and assessment 
as well as increased monitoring of both the patient and the 
therapeutic characteristics that modulate treatment outcome 
(Holtzheimer et al 2004).
Another experimental application of TMS has been 
magnetic seizure therapy (MST), the use of rTMS at high 
stimulus frequency and intensity to deliberately induce a 
generalized seizure under anesthesia for the treatment of 
depression (Morales et al 2004). MST stimulation is more 
focal than that of ECT, thus leading to the expectation of 
fewer cognitive side effects. So far, preliminary trials in 
nonhuman primates and human subjects have conﬁ  rmed 
this expectation, while case reports have found that MST 
led to signiﬁ  cant improvement in two medication-resistant 
depressed subjects (Morales et al 2004).
Bipolar disorder
There have been a number of case reports of the induction 
of mania in depressed subjects receiving rTMS treatment 
(Garcia-Toro 1999; Dolberg et al 2001; Sakkas et al 2003; 
Su 2005; Hausmann et al 2004b). Grisaru et al (1998a) 
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Figure 1 Illustration of brain regions affected by the physical treatments transcranial magnetic stimulation (a), vagus nerve stimulation (b), deep brain stimulation (c), and 
neurosurgery (d).
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Table 1 TMS/sham controlled studies
Study N Design/RTMS treatment Mean % change HDRS4 Number of responders5
Pascual-Leone et al
1996
17 Multiple crossover: L and R DLPFC (active/sham),
vertex (active) 10 Hz1, 5 days2
L DLPFC active: 48%,
Other: 4%–12%
L DLPFC active: 4
Other: 0
George et al 1997a 12 Crossover: L DLPFC (active/sham), 20 Hz, 10 days Active: 16%
Sham: 13%↑
Active: 1
Sham: 0
Loo et al 1999 18 Parallel: L DLPFC (active/sham), 10 Hz, 10 days Active: 23%
Sham: 25%
Active: 0
Sham: 1
Padberg et al 1999 18 Parallel: L DLPFC (active) 10 Hz/0.3 Hz,
(sham) 10 Hz, 5 days
10 Hz: 6%
0.3 Hz: 19%
Sham: 6% ↑
All: 0
Klein et al 1999 70 dep Parallel: R DLPFC (active/sham), 1 Hz, 10 days Active: 47%
Sham: 22%
Active: 17/35
Sham: 8/32
Berman et al 2000 20 Parallel: L DLPFC (active/sham), 20 Hz, 10 days Active: 39%
Sham: 0.5%
Active: 1
Sham: 0
Eschweiler et al 2000 12 Crossover: L DLPFC (active/sham), 10 Hz, 5 days Active: 22%
Sham: 7%↑
?6
George et al 2000a 30 Parallel: L DLPFC (active) 20 Hz/5 Hz,
(sham) 20 Hz/5 Hz, 10 days
20 Hz: 26%
5 Hz: 48%
Sham: 21%
20 Hz: 3
5 Hz: 6
Sham: 0
Garcia-Toro et al 2001 28 Parallel: L DLPFC (active / sham), 20 Hz, 10 days Active: 38%
Sham: 34%
Active: 4
Sham: 3
Lisanby et al 2001 36 Parallel: L DLPFC (active) 10 Hz,
R DLPFC (sham) 1 Hz
L DLPFC: 21%
R DLPFC: 20%
Sham: 13%
?
Manes et al 2001 20 Parallel: L DLPFC (active/ sham), 20 Hz, 5 days Active: 37%
Sham: 32%
Active: 3
Sham: 3
Dolberg et al 2002 20 Parallel, 10 days Active: 29%
Sham: 17%
?
Padberg et al 2002 30 Parallel: L DLPFC (active) 100% MT3, 90% MT,
(sham) 10 Hz, 10 days
100%: 30%
90%: 15%
Sham: 7%
100%: 3
90%: 2
Sham: 0
Loo et al 2003 19 Parallel: Bilateral prefrontal (active/sham),
15 Hz, 15 days
Active: 24%
Sham: 21%
Active: 2
Sham: 1
Nahas et al 2003 23 Parallel: L DLPFC (active/sham), 5 Hz, 10 days Active: 25%
Sham: 25%
Active: 4
Sham: 4
Hoppner et al 2003 30 Parallel: L DLPFC (active) 20 Hz, R 1 Hz,
(sham) L 20 Hz, 10 days
L 20 Hz: 17%
R 1 Hz: 10.5%
Sham: 23%
L 20 Hz: 5
R 1 Hz: 3
Sham: 5
Fitzgerald et al 2003 60 Parallel: L DLPFC (active) 10 Hz, R DLPFC 1 Hz,
(sham) L 10 Hz/ R 1 Hz, 10 days
MADRSL 10 Hz: 13.5%
R 1 Hz: 15%
Sham: 0.76%
L 10 Hz: 8
R 1 Hz: 7
Sham: 2
Jorge et al 2004 20 Parallel: L DLPFC (active/ sham) 10 Hz, 10 days Active: 38%
Sham: 13%
Active: 3
Sham: 0
Kauffmann et al 2004 12 Parallel: R DLPFC (active/ sham) 1 Hz, 10 days Active: 48%
Sham: 30%
Active: 4
Sham: 2
Holtzheimer et al 2004 15 Parallel: L DLPFC (active/sham) 10 Hz, 10 days Active: 32%
Sham: 28%
Active: 2
Sham: 1
Mosimann et al 2004 24 Parallel: L DLPFC (active/ sham) 20 Hz, 10 days Active: 20%
Sham: 17%
Active: 4
Sham: 0
Hausmann et al 2004 41 Parallel: L DLPFC (active) 20 Hz,
L DLPFC 20 Hz + R DLPFC 1 Hz,
(sham) L 20 Hz + R 1 Hz, 10 days
Active (both groups): 
30.6%
Sham: 24.8%
?
Koerselman et al 2004 55 Parallel: L DLPFC (active/ sham), 20 Hz,10 days Active: 18.5%
Sham: 15.4%
?
Rumi et al 2005 46 Parallel: L DLPFC (active/sham) 5 Hz, 20 days Active: 57%
Sham: 35%
Active: 21
Sham: 11
1 Hz, frequency of TMS pulses.
2 days, duration of TMS treatment in sham-controlled period.
3 % MT, % of subject’s resting MT.
4 Decreases in HDRS (Hamilton 1960) scores except where otherwise indicated.
5 Deﬁ  ned as   50% decrease in HDRS from baseline.
6 information not available.
Abbreviations: L DLPFC, left dorsolateral prefrontal cortex; MADRS, Montgomery Asberg Depression Rating Scale (Montgomery and Asberg 1979); R DLPFC, right 
dorsolateral prefrontal cortex; TMS, transcranial magnetic stimulation; MT, motor threshold.Neuropsychiatric Disease and Treatment 2006:2(2) 169
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published the ﬁ  rst trial of rTMS for the treatment of acute 
mania, randomizing patients to receive high-frequency 
rTMS to the left or right prefrontal cortices. Right prefrontal 
stimulation appeared to have an anti-manic effect with 
71% mean improvement on the Young Mania Rating Scale 
(Young et al 1978), whereas left prefrontal stimulation was 
associated with 29% mean improvement. Taken together 
with the results of depression trials demonstrating efﬁ  cacy 
for high-frequency left prefrontal rTMS, these ﬁ  ndings 
suggest that rTMS to the left and right prefrontal cortices 
respectively may have opposing effects. In further open 
studies, Saba et al (2002) and Michael and Erfurth (2004) 
also reported that rTMS may be a useful add-on treatment 
to medication in acute mania. However, the only sham-
controlled study of rTMS in mania, which used the exact 
same rTMS parameters as in the study by Grisaru et al 
(1998a), failed to ﬁ  nd any advantage for right prefrontal 
rTMS over sham (Kapstan et al 2003).
Schizophrenia
Left prefrontal high-frequency rTMS and right prefrontal 
low-frequency rTMS have also been trialled as treatments 
in patients with schizophrenia (Cohen et al 1999; Klein et al 
1999; Rollnik et al 2000; Hajak et al 2004; Holi et al 2004). 
Results have shown variable degrees of improvement in 
positive and negative symptoms and in mood. The incon-
sistent ﬁ  ndings of the sham-controlled studies (Klein et al 
1999; Rollnik et al 2000; Hajak et al 2004; Holi et al 2004) 
can perhaps be partly explained by the effect of interaction in 
that daily attendance required by the rTMS treatment protocol 
may have accounted for some of the changes observed, 
particularly any reduction in negative symptoms.
Some sham-controlled studies have reported that slow 
TMS over the left auditory cortex can reduce auditory 
hallucinations (Hoffman et al 2000, 2003; Poulet et al 2005). 
Others have failed to ﬁ  nd any signiﬁ  cant effects (McIntosh 
et al 2004; Schonfeldt-Lecuona et al 2004) despite the use of 
individual fMRI to speciﬁ  cally identify and target the cortical 
sites for inner speech production, thought to be involved in 
the production of hallucinations. Some of the inconsistencies 
in ﬁ  ndings may also be explained by a lack of consensus for 
rating of auditory hallucinations.
Other psychiatric disorders
There have been preliminary reports examining the use of 
rTMS in the treatment of other psychiatric disorders such 
as obsessive-compulsive disorder (OCD) (Sachdev et al 
2001a; Alonso et al 2001), post traumatic stress disorder 
(Grisaru et al 1998; McCann et al 1998a; Cohen et al 2004), 
and Tourette’s syndrome (Chae et al 2004). There have also 
been reports of high-frequency rTMS exacerbating anxiety 
and panic (Greenberg et al 1997) and low-frequency rTMS 
alleviating panic disorder (Zwanzger et al 2002). The role 
of rTMS in these disorders is at present unclear.
Neurological disorders
TMS has been investigated particularly in patients with 
Parkinson’s disease and epilepsy. In Parkinson’s disease, 
rTMS has been administered in an attempt to treat bradyki-
nesia and improve motor control. During movement, simul-
taneous stimulation of the motor cortex has been reported 
to be of no beneﬁ  t (Ghabra et al 1999) and stimulation of 
the supplementary motor area has been shown to worsen 
ﬁ  ne movements (Cunnington et al 1996). Other studies 
stimulating the PFC have noted modest beneﬁ  ts (Sommer 
et al 1998; Shinamoto et al 1999; Siebner et al 1999), some 
researchers suggesting that rTMS can diminish bradykine-
sia and enhance motor speed (Sommer et al 1998; Siebner 
et al 1999).
Interestingly, the application of TMS is associated with 
a measurable risk of seizure induction and yet, paradoxi-
cally, it has been found to be relatively safe in patients with 
epilepsy (Tassinari et al 1990). Indeed, it may in fact be an 
effective means of reducing seizure activity (Tegaru et al 
1999; Menkes and Gruenthal 2000; Werhahn et al 2000), 
although further research is needed.
Investigational applications of TMS
In cognitive neuroscience TMS has proven to be a versatile 
and valuable investigational tool, and has been used to 
examine cortical excitability and various aspects of brain 
cognition. It has been applied to the motor cortex in humans 
to examine motor evoked potentials (MEP) and motor thresh-
old (MT). MT is the stimulus intensity required to elicit 
MEP and in any given individual is relatively constant with 
interhemispheric differences, but is subject to modulation 
by drugs and disease.
Paired pulse TMS (ppTMS)
Paired pulse TMS involves the application of a pair of 
stimuli separated by a variable inter-stimulus interval. The 
ﬁ  rst stimulus is subthreshold whereas the second is above 
the threshold. Varying the inter-stimulus interval allows 
modulation of the overall response to the paired stimuli 
such that response can be facilitated or inhibited. Facilita-
tion can usually be achieved with an inter-stimulus interval Neuropsychiatric Disease and Treatment 2006:2(2) 170
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of 10–20 msec, and on either side of this (shorter or longer), 
inhibition is more likely. Neurochemically, inhibition and 
facilitation are mediated by gamma-amino butyric acid 
(GABA) and glutamate respectively.
When a TMS pulse elicits a MEP against a background 
of voluntary muscle contraction, the background activity is 
suppressed for a period after the MEP. This “silent period” 
is considered another measure of inhibitory cortical activity 
(Pascual-Leone et al 2002a).
Psychiatric disorders
The above TMS testing paradigms have been used to 
investigate abnormalities in cortical inhibitory and 
facilitatory processes in the motor cortex of patients with 
psychiatric disorders (Maeda and Pascual-Leone 2003). 
In schizophrenia, abnormalities have been reported in the 
MEP response to single pulse TMS (Abarbanel et al 1996; 
Puri et al 1996), and in silent period measurements and 
response to paired pulse stimulation (Daskalakis et al 2001; 
Fitzgerald et al 2001), suggesting a reduction in cortical 
inhibitory processes. However, these investigations were 
mostly done in medicated patients, and alterations in motor 
cortical functioning in the presence of antipsychotic medica-
tion have been demonstrated elsewhere (Ziemann et al 1997; 
Pascual-Leone et al 2002b).
Several studies have reported increased cortical inhibition 
(Steele et al 2000) or reduced post-exercise cortical facilita-
tion in depressed subjects (Samii et al 1996; Shajahan et al 
1999), though others have reported that the latter ﬁ  ndings 
appeared to be nonspeciﬁ  c, occurring also in patients with 
mania and schizophrenia (Chroni et al 2002). There are 
also preliminary reports of abnormalities in motor cortical 
functioning in OCD (Greenberg et al 2000), and Tourette’s 
syndrome (Ziemann et al 1997).
Cognition
TMS is increasingly being used in neuropsychological 
investigations (eg, Li et al 2004). During TMS or rTMS, 
functioning of the stimulated cortical area can be temporarily 
disrupted, creating in effect a “virtual lesion”. This technique 
can then be applied to examine the cortical sites involved 
in a particular function and the critical time periods of their 
involvement (Pascual-Leone et al 1999). For example, rTMS 
can be used to noninvasively identify the lateralization of 
verbal functions (Epstein 1998). Studies of the frontal and 
prefrontal cortex have examined aspects of memory and 
word generation (Grafman et al 1994; Jahanshahi et al 1998). 
For example, Devlin et al (2005) have recently demonstrated 
that TMS-induced interference in the left inferior prefrontal 
cortex has an effect on semantic but not perceptual process-
ing. TMS can also enhance neuropsychological functioning 
when administered to speciﬁ  c cortical areas with precise 
timing, eg, picture naming (Topper et al 1998).
Clearly, this innovative ﬁ  eld of research has expanded 
tremendously with the introduction of TMS as an investi-
gative tool and is an area of research that is likely to yield 
many new insights into the functioning of the normal and 
diseased brain.
Overall, TMS remains a useful tool for the investigation 
of abnormal physiological processes in psychiatric disorders. 
Further research in larger samples of unmedicated subjects is 
needed before deﬁ  nitive conclusions can be made.
Adverse effects
TMS has few adverse effects as it is relatively noninvasive. 
The risks that are associated with its use are determined 
largely by the number, intensity, and frequency of stimuli 
applied. Occasionally, rTMS results in a headache that 
may last several hours. Some subjects complain of scalp 
discomfort during TMS, attributable to the associated 
stimulation of muscles and nerves near the coil. Low fre-
quency TMS and ppTMS are unlikely to produce seizures, 
or have any lasting effects on cognition, but rTMS, by 
increasing cortical excitability, can precipitate seizures 
even in healthy subjects, though the risk is very low 
(Wassermann 1998).
It is important to note that TMS can cause a temporary 
shift in auditory threshold and to protect patients from this 
during stimulation a set of precautionary earplugs should be 
worn (Wassermann 1998).
Vagus nerve stimulation (VNS)
The vagus nerve or the Xth cranial nerve is a mixed nerve, 
composed predominantly of sensory afferents carrying 
information from the thorax, abdomen, head, and neck to the 
brain. Cell bodies of these vagus-sensory afferents lie pre-
dominantly in the nodose ganglion and project information 
primarily to the nucleus tractus solitarius (NTS) as well as the 
area postrema, the spinal trigeminal nucleus, the medullary 
reticular formation, the dorsal nucleus of the vagus, and the 
nucleus ambiguous (Henry 2002). Information is conveyed 
via these direct projections and by an autonomic feedback 
loop to the rest of the brain and ascending projections to the 
forebrain which travel via the parabrachial nucleus and the 
locus coeruleus. These structures have direct connections 
with the forebrain, thalamus, hypothalamus, amygdala, and Neuropsychiatric Disease and Treatment 2006:2(2) 171
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stria terminalis – regions that are important in the modulation 
of mood (George et al 1997b; Van Bockstade et al 1999). 
Vagus nerve projections attend brain regions that are 
thought to be involved in several neuropsychiatric disorders 
presenting the potential for VNS to have several important 
clinical roles in addition to its use in treating epilepsy and 
depression.
In humans, VNS involves stimulation of the left cervical 
vagus nerve using a commercial device – the Neuro-
Cybernetic Prosthesis (NCP) System (Schacter and Saper 
1998). This device comprises a bipolar pulse generator, 
electrodes, and a programming wand. The generator is 
implanted in the left chest wall below the clavicle and delivers 
electrical signals via a bipolar lead to an electrode that is 
wrapped around the vagus nerve in the neck (see Figure 1b). 
Implantation usually takes less than an hour and can be 
conducted under general or local anesthesia (Amar et al 
1998). On-line modiﬁ  cation and data retrieval are possible 
as a proprietary instrument is used to program the pulse 
generator. The latter can be stopped brieﬂ  y using a hand 
held magnet but stimulus interruption does not interfere with 
preprogrammed stimulation which automatically resumes 
when the magnet is displaced (George et al 2000b).
VNS reduces the excitability of neurons involved in the 
propagation of seizure activity (Zagon and Kemeny 2000); 
however, its exact mechanisms of action remain unknown 
though it is thought to produce slow hyperpolarization. EEG 
and neuroimaging data, using single photon emission com-
puted tomography, implicate the thalamus (Ring et al 2000; 
Vonck et al 2000), inhibition of which may prevent the onset 
or propagation of seizures (Van Laere et al 2000).
Efﬁ  cacy
To date, the main use of VNS has been to reduce seizure 
frequency in both adults (Ben-Menachem et al 1994; 
Handforth et al 1998; Morrow et al 2000; Wakai and Kotagal 
2001) and children (Patwardhan et al 2000; Wakai and 
Katagal 2001) with treatment-resistant epilepsy. Improve-
ments gained appear to be sustained and may continue with 
time (Salinsky et al 1995; DeGiorgio et al 2000).
Two studies have shown an improvement in mood in 
epileptic patients receiving VNS compared with controls 
(Harden et al 1999; Hoppe et al 2001) and such observations 
have led researchers to hypothesize that it may be effective 
in treating mood disorders (Harden et al 1999; Elger et al 
2000). The fact that it increases central noradrenergic and 
serotonergic neurotransmission would be in keeping with 
such a hypothesis (Krahl et al 1998; Jobe et al 1999), and in 
common with other effective antidepressant therapies it 
alters limbic system blood ﬂ  ow, involving in particular the 
cingulate (Henry et al 1999).
Open studies to examine the effects of VNS on mood 
have been conducted in treatment-resistant depressed 
patients (Rush et al 2000; Sackeim et al 2001). In a multi-
center study, 30 depressed patients (n = 21; nonpsychotic 
treatment-resistant major depression, n = 4; bipolar, and 
n = 5 bipolar II) underwent 10 weeks of VNS after which 
40% of patients reported having a signiﬁ  cant reduction in 
mood-scale scores (Ham-D and MADRS). These ﬁ  ndings 
were sustained during long-term follow-up (Rush et al 
2000). Further preliminary studies (Kosel and Schlaepfer 
2003) also suggest that VNS has antidepressant properties; 
however, there is a need for larger controlled trials and at 
least one is currently underway (Schlaepfer and Kosel 2004). 
Several recently published studies provide preliminary 
support for VNS having an antidepressant role. Firstly, in a 
multicenter trial Rush et al (2005a) compared the effects of 
10 weeks’ active as opposed to sham VNS in 222 participants 
with treatment-resistant depression. They found VNS was 
linked with greater symptom reduction across measures but 
the ﬁ  nding did not reach signiﬁ  cance and hence could not 
be considered deﬁ  nitive evidence of its efﬁ  cacy. This group 
subsequently published further results of a one-year open 
trial involving patients who had completed the initial acute 
phase (Rush et al 2005b). The results from 205 participants 
in this study revealed statistically signiﬁ  cant reduction 
in depressive symptoms and despite the lack of a control 
group and nonmasking of ratings, these data seem to sup-
port further investigation of VNS as an antidepressant. 
Finally, George et al (2005) compared the results from 
the one-year open trial with the results from a comparable 
treatment-as-usual (TAU) group. The primary analysis in 
this study yielded a signiﬁ  cant difference between the groups 
favoring VNS plus TAU over TAU alone. The addition of 
VNS to TAU resulting in improved response supports its 
role as an antidepressant, although this still requires further 
investigation.
VNS was initially approved in the US by the FDA for 
the treatment of epilepsy in 1997 and just recently (July 
2005) the VNS therapy system has been approved to treat 
depressed patients of 18 years and over who have not 
had a response to four or more trials of an antidepressant 
(Cyberonics website 2005). It has also been approved for 
use in the treatment of depression in the EU and Canada. It 
would be useful to extend VNS trials to include depressed 
patients other than those who are treatment resistant, in order Neuropsychiatric Disease and Treatment 2006:2(2) 172
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to examine its differential efﬁ  cacy across depressive subtypes 
and also its effects on cognition (Schacter 2004).
Adverse effects
The adverse effects of VNS are, ﬁ  rstly, those associated 
with the procedure of implantation and, secondly, those 
that occur as a consequence of stimulation. Surgical adverse 
effects include pain, coughing, left-vocal cord paralysis, 
hoarseness, nausea, and very occasionally infection. Most 
patients describe these as a moderate inconvenience and the 
effects are usually transient (Schachter and Saper 1998). 
Of note, during implantation, there have been no deaths and 
no reports of serious adverse events such as the alteration 
of cardiac or pulmonary function. However, transient asys-
tole has occurred in a small number of patients when the 
stimulator is ﬁ  rst activated during in-theatre testing. The 
most signiﬁ  cant stimulation-related adverse effects are those 
of dyspnea and voice-alteration (Charous et al 2001), which 
can be reversed by application of the hand-held magnet and 
prevented by lowering the stimulation current (Schachter 
and Sapel 1998).
Deep brain stimulation (DBS)
In the management of Parkinson’s disease (PD) and other 
movement disorders DBS is an important treatment that 
appears to have an additional antidepressant effect without 
causing any global cognitive deterioration (Funkiewiez et al 
2004). In PD, neural degeneration and transmitter deﬁ  cien-
cies lead to neural dysfunction and abnormal activity in motor 
system relays such as the thalamus, the internal segment 
of the globus pallidus (GPi) (Miller et al 1987), and the 
subthalamic nucleus (STN) (Wichmann et al 1994), with 
the last emerging as the most popular target for treatment 
interventions (Breit et al 2004).
Using implanted quadripolar electrodes connected to 
a battery-powered pulse-generating device (see Figure 1), 
DBS delivers an electrical current, the strength of which 
can be adjusted by varying electrode selection and polarity 
and by altering frequency, amplitude and pulse-width. In the 
treatment of PD, parameters that are typically used include 
a voltage of more than 3 V with a pulsewidth of 60–90 μsec 
and a frequency of 150–185 Hz (Lozano 2001).
The mechanism of action of DBS, like other physical 
treatments, is unknown but both clinical and exper  imental 
evidence indicate that the frequency of stimulation 
affects clinical outcome. Breit et al (2004) outline the 
main hypotheses that account for the benﬁ  cial effects of 
high frequency stimulation as follows: the effect is due to 
depolarization blocking neuronal transmission through 
inactivation of voltage-dependent ion channels; the jamming 
of information imposes an efferent stimulation-driven high 
frequency pattern; stimulation of inhibitory afferents results 
in synaptic inhibition to the target nucleus; and stimula-
tion induces neurotransmitter depletion, and hence causes 
synaptic depression. This explanation is corroborated to some 
extent by animal models of PD in which there is increased 
basal spontaneous activity in the STN that drives GPi nucleus 
inhibitory outﬂ  ow. The outﬂ  ow in turn inhibits motor systems 
within the thalamus, brainstem, and cortex and results in the 
akinesia and bradykinesia of PD (DeLong and Wichmann 
2001). Hence the rationale for surgical intervention is to 
interrupt the excessive inhibition from these nuclei (Lang 
et al 1999). Electrical stimulation achieves this by producing 
neuronal inactivation either by direct disruption of neuronal 
activity or by increasing GABA-mediated inhibitory neuro-
transmission. Interestingly, the afferents that impinge upon 
neurones in the GPi nucleus and STN are rich in GABA 
(see Figure 1c).
Indications for DBS in PD include advanced idiopathic 
illness with motor complications, tremor, and related dis-
ability. With GPi or STN DBS the symptoms of PD can 
be improved by up to 80% and in many cases the use of 
concurrent medications can be signiﬁ  cantly reduced if 
not stopped altogether (Limousin et al 1998; Volkmann 
et al 1998). Vim thalamus DBS has a greater speciﬁ  city 
of action and is effective in alleviating the tremor of PD 
in up to 80% of patients; however, unlike DBS applied to 
the GPi and STN, it fails to produce signiﬁ  cant functional 
improvement and has few additional beneﬁ  ts (Schuurman 
et al 2000) such as alleviating motor ﬂ  uctuations, brady-
kinesia, gait disturbances, and drug-induced dyskinesias. 
Not surprisingly, GPi and STN DBS are being increas-
ingly favored and there is now almost no indication for 
Vim thalamus DBS as these treatments are far superior in 
effect. The disadvantage of this trend is that speech and 
cognition are less responsive and some of the problems 
that patients face can in fact be exacerbated by surgery 
(Limousin et al 1998).
Efﬁ  cacy
As a treatment DBS has the advantage of being precise and 
reversible (Greenberg and Rezai 2003), a clear advance 
in comparison to neurosurgery for intractable psychiatric 
disorders (Rees Cosgrove 2004; Kopell et al 2004). 
Furthermore, the strength of stimulation can be controlled 
allowing treatment to be adjusted according to individual Neuropsychiatric Disease and Treatment 2006:2(2) 173
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needs, which has made it an increasingly popular choice for 
the treatment of refractory PD.
DBS has also been found to be beneﬁ  cial in two of three 
cases of treatment refractory OCD described by Gabriels et al 
(2003). Aouizerate et al (2004) describe DBS of the ventral 
caudate nucleus as effective in improving functioning and 
achieving remission in a patient with intractable severe OCD 
and concomitant major depression. Lonzano and Hamani 
(2004) report an increase in the number of applications 
for DBS, indicating recognition of its potential for treating 
neuropsychiatric disorders as well as its continued importance 
in the treatment of movement disorders.
Adverse effects
Predictably, the adverse effects associated with DBS are 
largely the consequence of surgery as opposed to stimula-
tion. One of the most common side-effects is that of tran-
sient confusion; More serious side-effects can also occur 
although the likelihood is less than 2%. Stimulation is also 
associated with speech disturbance, paraesthesiae, eye 
movement difﬁ  culties, and motor contractions. Complica-
tions can also arise because of device failure; however, 
this is easily remedied by replacement of the necessary 
components.
Neurosurgery
Psychosurgery has been “practised” since antiquity 
involving trephination thought to release “evil spirits”. 
At the beginning of the twentieth century neurosurgery 
experienced a resurgence of interest; however, the devel-
opment of psychotropic medications largely eliminated 
the need for standard prefrontal leucotomy (Freeman and 
Watts 1942), which was used to “treat” schizophrenia and 
affective psychoses (Tooth and Newton 1961). However, 
neurosurgery for mental disorders has survived in modiﬁ  ed 
form and in many parts of the world remains a treatment 
option for neuropsychiatric illnesses where all other options 
have been exhausted.
Modern-day neurosurgical procedures, although more 
reﬁ  ned and sophisticated, continue to target the limbic 
system and its connections, particularly frontal lobe circuits 
that involve striatal structures such as the thalamus and 
caudate (Cummings 1993). Currently, four neurosurgical 
procedures are performed worldwide namely: cingulotomy, 
stereotactic subcaudate tractotomy (SST), anterior capsu-
lotomy (AC), and limbic leucotomy (LL) (Malhi et al 1997), 
with the last in essence combining the lesions of the ﬁ  rst 
two (Kelly et al 1973) (see Figure 1d). The indications, 
ablative techniques, lesion sites, and targets of these 
procedures are summarized in Table 2.
It is noteworthy that all three neurosurgical lesions 
interrupt the interconnecting pathways of the limbic system 
and the prefrontal cortex, in particular the amygdalofugal 
pathways and those of the limbic loop, explaining perhaps 
the overlapping effects of these procedures.
Efﬁ  cacy
Psychosurgery for psychiatric disorders is almost always 
considered a treatment of last resort and as a consequence 
psychiatric patients that undergo surgical procedures are by 
deﬁ  nition treatment refractory. Nevertheless, in countries 
where these procedures are available, strict regulations 
govern the selection and consent of patients to ensure that 
all reasonable alternatives have been adequately explained 
(Clinical resource audit group 1996).
In the treatment of OCD, psychosurgery has been 
reasonably effective with significant improvement in 
40%–60% of cases undergoing anterior capsulotomy (Mindus 
and Nyman 1991; Mindus and Jenike 1992; Rasmussen et al 
2000). In comparison, SST has generally been less helpful in 
OCD, with improvement occurring in only a third of patients 
(Hodgkiss et al 1994); however, it is effective in mood 
disorders, with more than a third of patients achieving a good 
outcome (Hodgkiss et al 1994; Malizia 1994; Poynton et al 
1995; Malhi and Bartlett 2000). Recently, the mechanism of 
action of SST in depression has been investigated (Dalgleish 
et al 2004), with improvement thought to occur by way 
of an acquired insensitivity to negative information. This 
interesting but provocative suggestion warrants further 
investigation.
In addition to its use in OCD, capsulotomy has also been 
used to treat refractory social phobia, generalized anxiety 
disorder, and panic disorder. Long term it appears to produce 
a notable reduction in anxiety, with 67% of subjects show-
ing signiﬁ  cant response (Ruck et al 2003); however, con-
cerns have been raised as to whether the procedure causes 
frontal lobe dysfunction, which may be masked by seeming 
improvement.
In contrast to capsulotomy and SST, cingulotomy 
introduced by Fulton and reﬁ  ned by Ballantine et al (1997) 
(Mashour et al 2005) has been used almost exclusively 
to treat OCD with reasonable success in approximately 
one third of patients (Jennike et al 1991), and because of 
the conservative nature of the procedure many patients 
beneﬁ  t from a second operation to extend the original 
lesion. However, worsening of obsessionality has also Neuropsychiatric Disease and Treatment 2006:2(2) 174
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been described, with one study reporting pre-operative 
obsessive traits predisposing epileptic patients to develop 
OCD (Kulaksizoglu et al 2004).
Limbic leucotomy has been less widely used than the 
other procedures but has been utilized to treat a broad range 
of symptoms with modest success (treatment response of 
36%–50%) in patients with major depression and OCD 
(Montoya et al 2002).
Adverse effects
All surgery confers some degree of risk and this is particularly 
true of neurosurgery in as the operation involves structural 
reorganization of cortical matter. The most common com-
plaints following SST are confusion, a transient lack of 
sphincter control, and lethargy, with the latter persisting 
beyond one week in 12% of patients (Malhi et al 1997). These 
are similar to the adverse effects associated with AC except 
that no deaths have been reported and documented seizures 
have been rare. Similarly, cingulotomy has not resulted in any 
reported deaths, and reports of seizures are scarce; however, 
it has caused two cases of hemiplegia (Ballantine et al 1987; 
Marino Junior and Cosgrove 1997).
Despite the relative safety of these procedures, concerns 
remain about the effects of neurosurgical procedures on 
personality and behaviour (Happe et al 2001) and there is 
some evidence to suggest that frontal lobe deﬁ  cits such 
as disinihibition, apathy, and cognitive inﬂ  exibility have 
occurred following cingulotomy (Irle et al 1998; Ruck et al 
2003). Cumming et al (1995) also found no differences 
between post-surgical patients and controls on tests of 
memory and global ability; however, there were deﬁ  cits 
present in formation and shifting of set. Bejerot (2003) makes 
the point that many patients are asked to self-report on 
symptoms post-operatively and that the validity of information 
gathered in this context is questionable, especially if patients 
have compromised frontal lobe function.
Discussion
Limited knowledge of the neuropsychiatric disorders 
themselves, as well as the mechanisms underpinning physical 
treatments, continues to hamper growth in this ﬁ  eld that is 
further constrained by a tendency for polarization of opinions 
in relation to its evidence base and ethics. Thus far, TMS is 
the only physical treatment that has acquired a ﬁ  rm footing, 
with studies demonstrating its efﬁ  cacy in the treatment of 
depression. Equally valuable is its application into research 
where it has been used to create “virtual lesions”. Its relative 
noninvasiveness and acceptance by patients have made it a 
popular therapy.
More invasive treatments such as DBS and VNS offer 
greater control than neurosurgery by allowing stimulation 
to be titrated to achieve an optimal response. In some cases 
the speciﬁ  city of these interventions makes them prefer-
able to pharmacotherapy which, although more widely 
acceptable, is relatively blunt as regards site of action and 
timing of effect. With respect to the latter, DBS produces 
effects over a matter of milliseconds, in tune with the 
electrophysiology of the brain. It is therefore potentially 
capable of mimicking normal physiological function and 
its use in the management of PD has paved the way for 
wider application. Initial studies of its efﬁ  cacy in the treat-
ment of refractory psychiatric illnesses are encouraging. 
Similarly, the application of VNS has expanded beyond 
its role as an “anticonvulsant” to studies examining its 
Table 2 Neurosurgical procedures used in the treatment of neuropsychiatric disorders
Neurosurgical
procedure Indications Ablative technique Lesion Target
Anterior capsulotomy OCD and anxiety 
disorders
Gammacapsuolomy (gamma knife 
focuses 200+ beams of cobalt60 
gamma radiation upon a designated 
point)
Anterior limb of internal 
capsule (between head 
of caudate nucleus and 
putamen)
Neuronal tracts 
connecting thalamus and 
orbito-frontal cortex
SST Affective disorders
(UP/BP) 
Anxiety Disorders 
OCD
Radiofrequency electrocoagulation 
supplanted yttrium in 1997
White matter beneath 
and just anterior to the 
head of the caudate nucleus
Fibres connecting 
prefrontal cortex and 
dorsomedial nucleus of 
thalamus
Cingulotomy OCD (primarily) and 
affective/ anxiety
disorders
Radiofrequency thermocoagulation Cingulum (1 cm in width 
extending 2 cm dorsally 
from the corpus callosum)
Thalamofrontal neuronal 
loops
After Knight 1965; Strom-Olsen and Carlisle 1971; Bingley et al 1973; Newcombe 1975; Goktepe et al 1975; Bartlett et al 1977; Alexander et al 1986; Ballantine et al 1987; 
Meyerson and Mindus 1988; Alexander et al 1990; Jennicke et al 1991; Mindus 1993; Devinsky et al 1993; Ebert and Ebmeier 1996; Marino Junior and Cosgrove 1997; Osview 
and Frim 1997; Malhi and Barlett 1998.
Abbreviations: BP, bipolar; OCD, obsessive-compulsive disorder; SST, stereotactic subcaudate tractotomy; UP, unipolar.Neuropsychiatric Disease and Treatment 2006:2(2) 175
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antidepressant properties. A recent study indicated 15.5% 
of patients with treatment-resistant depression achieved 
sustained remission compared with 4.6% of the participants 
receiving treatment as usual (George et al 2005). Recently, 
it has been approved as an antidepressant treatment in the 
EU and Canada, and this opens up the possibility of its 
application in a range of psychiatric illnesses including pain 
syndromes, addictions, and eating disorders.
Somewhat surprisingly neurosurgery has regained 
popularity as an effective treatment for refractory psychiatric 
disorders, even though it is still considered only following 
the failure of traditional methods. Part of the reason for 
this is its apparent success in a patient population that has a 
very low rate of placebo response. However, psychosurgical 
research has been plagued by the lack of standardized 
nosology and the inherent referral bias, as patients under-
going such procedures are clearly not representative of the 
respective phenotypes to which they belong. Clearly, the fact 
that few procedures are performed and they are necessarily 
invasive limits the prospects of sham-controlled prospective 
studies. Improvements in technology and surgical techniques 
with increasing sophistication of instrumentation will likely 
make such studies possible in the future. However, in the 
interim research along the lines of Dagliesh et al (2004) 
has shed light on the speciﬁ  c cognitive processes altered 
by such procedures and is likely to inspire greater clinical 
conﬁ  dence.
Conclusion
In the past decade physical interventions have once again 
captured the imagination of neuroscientists and clinicians 
alike. However, in comparison with pharmacological 
treatments they remain under-researched due to a range of 
political, economic, and sociological factors. It is also difﬁ  -
cult to compare efﬁ  cacy rates of pharmacologically treated 
patients with those who receive physical interventions as 
the characteristics of the two groups vary substantially in 
terms of resistance, duration of illness, and prior treat-
ment. Despite this, these treatments provide novel insights 
into the neurobiology of these neuropsychiatric disorders 
and interventions such as TMS are beginning to establish 
themselves as viable therapeutic options. However, if his-
tory is not to repeat itself, the ﬁ  eld has to be cautious in 
its predictions and claims. Key advances in neuroimaging, 
for instance, have ensured much better localization and 
monitoring of the effects of these interventions but the 
longer-term effects have yet to be determined. In reality, 
each of the physical treatments described requires much 
further clinical investigation. Fortunately, this is at last 
a possibility and many researchers have taken up the 
challenge. It is hoped that in the coming decade some of 
these interventions in their modiﬁ  ed forms will become 
more widely accepted as mainstream treatments and ben-
eﬁ  t the many patients with intractable neuropsychiatric 
disorders.
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